1. I. P. Ashmarin, Glyprolines in as Part of Regulator Tripeptides. Neirokhimiya, 24, No. 1, 5-7 (2007).

2. N. A. Andreeva, E. V. Stel’mashuk, N. K. Isaev, R. U. Ostrovskaya, T. A. Gudasheva, and I. V. Viktorov, Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress. Bull. Exp. Biol. Med., 130, No. 10. 969-972 (2000).

3. T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, M. Yu. Kosoi, F. V. Ienkina, Yu. V. Burov, and A. P. Skodinov, Peptide analogs of Piracetam as ligands of assumed nootropic receptors. Khim.-Farm. Zh., 19, No. 11. 1322-1324 (1985).

4. R. U. Ostrovskaya, Yu. V. Vakhitova, M. Kh. Salimgareeva, R. S. Yamidanov, S. V. Sadovnikov, I. G. Kapitsa, and S. B. Seredenin, On the mechanism of noopept action: decrease in activity of stress-induced kinases and increase in expression of neutrophines. Eksp. Klin. Farmakol., 73, No. 12, 2-5 (2007).

5. K. S. Us, P. M. Klodt, V. S. Kudrin, R. U. Ostrovskaya, K. S. Rayevsky, A. Ya. Sapronova, and M. V. Ugryumov, The effect of the synthetic neuroprotective dipeptide Noopept on glutamate release from rat brain cortex slices. Neurochemical Journal, 1, No. 2, 138-142 (2007).

6. J. V. Bukanova, E. I. Solntseva, and V. G. Skrebitsky, Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons. Int. J. Neuropsychopharmacol., 5, No. 3, 229-237 (2002).

7. T. A. Gudasheva, T. A. Voronina, R. U. Ostrovskaya, G. G. Rozantsev, N. I. Vasilevich, S. S. Trofimov, E. V. Kravchenko, A., Skoldinov, and S. B. Seredenin, Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides. Eur. J. Med. Chem., 31, No. 2, 151-157 (1996).

8. P. Maher and J. B. Davis, The role of monoamine metabolism in oxidative glutamate toxicity. Neuroscience, 16, No. 20, 6394-6401 (1996).

9. A. Pelsman, C. Hoyo-Vadillo, T. A. Gudasheva, S. B. Seredenin, R. U. Ostrovskaya, and J. Busciglio, GVS-111 prevents oxidative damage and apoptosis in normal and Down’s syndrome human cortical neurons. Int. J. Dev. Neurosci., 21, No. 3, 117-124 (2003).

10. R. C. Petersen, R. Doody, A. Kurz, R. C. Mohs, J. C. Morris,, V. Rabins, K. Ritchie, M. Rossor, L. Thal, and B. Winblad, Current concepts in mild cognitive impairment. Arch. Neurol., 58, No. 12, 1985-1992 (2001).

11. R. Resende, C. Pereira, P. Agostinho, A., Vieira, J. O. Malva, and C. R. Oliveira, Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ homeostasis. Brain Res., 1143, 11-21 (2007).

12. S. B. Seredenin, T. A. Voronina, T. A. Gudasheva, R. U. Ostrovskaya, G. G. Rozantsev, A., Skoldinov, S. S. Trophimov, J. A. Halikas, and T. L. Garibova, US Patent No. 5439930 A. Biologically active N-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects, Published August 08, 1995.